SUZHOU - CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare disease, announced positive topline results from the CAN103 pivotal trial, in treatment-naive subjects aged 12 or above with Gaucher disease (GD) Types I and III.
The CAN103 pivotal trial is a randomized, double-blind, dose-comparison study designed to evaluate the efficacy, safety, and pharmacokinetics of intravenous CAN103 administered every other week in newly treated Gaucher Disease (GD) patients, with an extension period. The results demonstrate that the study successfully met its primary efficacy endpoint, showing a statistically significant mean percentage reduction from baseline in spleen volume at nine months for both the 60 U/kg dose (P
(C) 2024 Electronic News Publishing, source ENP Newswire